Brian Orelli, PhD

The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.

The move should be helpful as the DNA-sequencing specialist develops diagnostic tests that require his former agency's approval.

Rival GW Pharmaceuticals came out the big winner, as its competing seizure drug looks more effective.

Sometimes slow and steady wins the race.

Issues with its Alaris infusion system will take longer to fix, forcing the company to lower fiscal 2020 guidance.

The pharmaceutical giant's guidance also looks good.

A patent case win for its partner Biogen will give the duo time to convince multiple sclerosis patients to switch from Tecfidera to Vumerity.

The big pharma has the right to acquire the start-up later a predetermined price.

Gilead Sciences may be winning the race to develop the first coronavirus treatment.

Assuming the European Commission follows the recommendation of its scientific committee, this will be the fifth oncology biosimilar from Pfizer approved in Europe.

A scientific committee recommended approvals that could expand the sales of Venclyxto and Maviret.

2020 sales are expected to accelerate year over year, but so are expenses.

Its newer drugs are more than making up for the waning sales of older medications.

Share repurchases helped enhance the pharmaceutical giant's results.

The pharmaceutical giant got the precision medicine through its acquisition of Loxo Oncology.

The companies have jumped into the fray against the 2019-nCoV outbreak.

Management sees revenue growing faster in the second half of the fiscal year.

But the biotech won't release details about how well it works until later.

A successful midstage clinical trial has investors giddy, but the devil will be in the details.

The combination treatment offers patients more convenience, but could also help the duo fight off competition.